Cite
HARVARD Citation
Loriot, Y. et al. (n.d.). 920TiPErdafitinib compared with vinflunine or docetaxel or pembrolizumab in patients (pts) with metastatic or surgically unresectable (M/UR) urothelial carcinoma (UC) and selected fgfr gene alterations (FGFRalt): The phase III THOR study. Annals of oncology. p. . [Online].